Analysts have been eager to weigh in on the Healthcare sector with new ratings on Quidel Corp (QDEL) and Audentes Therapeutics (BOLD).
Quidel Corp (QDEL)
In a report released today, Jack Meehan from Barclays maintained a Buy rating on Quidel Corp, with a price target of $77. The company’s shares opened today at $48.01.
According to TipRanks.com, Meehan is a 4-star analyst with an average return of 4.7% and a 57.4% success rate. Meehan covers the Healthcare sector, focusing on stocks such as Bio-Rad Laboratories, IQVIA Holdings Inc, and Myriad Genetics.
Quidel Corp has an analyst consensus of Strong Buy, with a price target consensus of $77.67, which is a 61.8% upside from current levels. In a report released today, Piper Jaffray also maintained a Buy rating on the stock with a $73 price target.
.
See today’s analyst top recommended stocks >>
Audentes Therapeutics (BOLD)
In a report released today, Mohit Bansal from Citigroup maintained a Hold rating on Audentes Therapeutics, with a price target of $28. The company’s shares opened today at $23.53, close to its 52-week low of $19.62.
According to TipRanks.com, Bansal is ranked #912 out of 5108 analysts.
Audentes Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $37.83.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
